Latest From Biotech Now

“Let’s Take Advantage of It,” Biotech in the US-EU Trade Agreement

admin-ajax

As the second round of the Transatlantic Trade and Investment Partnership (TTIP) talks approach Brussels in October, several noteworthy articles remind us why biotech is such an important driving force in these discussions. Dean Kleckner, chairman emeritus for Truth About Trade & Technology (TATT), in recent articles in the Washington Times and Des Moines Register wrote a piece titled “Ending Flaky Trade Barriers,” highlighting challenges within the US-EU trade agreement and illustrating why biotech should Read More >

Food And Agriculture  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

12th Annual BIO Investor Forum Presenting Companies Announced

San Francisco skyline

Looking to lose a few pounds? Don’t want to diet or exercise? You’re not alone: fully one-third of Americans are obese, and many companies are trying to discover the first blockbuster diet drug and make a dent in the obesity epidemic. We’ll hear from one of those companies next month at the 12th Annual BIO Investor Forum, taking place October 8-9th in San Francisco. Cambridge-based Zafgen is hoping to bring to market their first-in-class obesity Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

CTTI: Use of Central IRBs in Multi-Center Trials to Streamline Clinical Research

Untitled-1

Multi-center clinical trials can provide high-quality, statistically-sound evidence to answer medical questions. Earlier this year, the Clinical Trials Transformation Initiative (CTTI) launched a new tool and provided recommendations to improve the efficiency and quality of multi-center clinical trials. Typically, each participating center submits the study protocol to its institutional review board (IRB). Thus in a multi-center trial, the same protocol is submitted to as many IRBs as there are sites. The process of multiple reviews Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

E&Y Study: 3 Tax Tweaks that Could Spur Job Growth

87881842

A new report from Ernst & Young illustrates the economic impact of three tax proposals intended to help small businesses spur innovative research and development. The report indicates that the three tax revisions, if enacted together, could drive up research and development investments by more than $20 billion and create an estimated 623,000 new jobs at new and small firms. The report outlines the potential impact of the three proposals, which include: The R&D partnership Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,